Oncology Medical News about osteosarcoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response
Journal of Orthopaedic Science, 06/10/09

Kim MS et al. - In a study to assessed volume changes after neoadjuvant chemotherapy and evaluate relations between tumor size changes and clinical characteristics as well as to determine whether tumor size change influences pt outcome, it appears that increased tumor volume after neoadjuvant chemotherapy independently shortened metastasis-free and overall survival (OS) in AJCC stage II osteosarcoma pts. Tumor volume changes may serve as a basis for risk-adapted therapy when used in combination with other prognostic factors.

Methods

Records of 127 pts with stage II osteosarcoma who showed more than a 15% volume change after chemotherapy were retrospectively reviewed.
Pts were divided into 2 groups depending on whether tumors increased or decreased in size.
Fisher’s exact test was performed to analyze correlations between tumor size changes and clinicopathological variables.
5-yr metastasis-free survival and OS were evaluated using univariate and multivariate analyses.

Results

71 pts (55.9%) showed a decrease in tumor volume, and 56 pts (44.1%) showed an increase.
An increase in tumor volume after neoadjuvant chemotherapy was positively correlated with a poor histological response and subsequent metastasis.
Univariate analysis identified the following parameters as poor prognostic factors: age ≤15 yrs, American Joint Committee on Cancer (AJCC) stage IIB, a subtype other than osteoblastic, poor histological response, and increased tumor volume after preoperative chemotherapy.
Multivariate analysis revealed that AJCC stage IIB and an increase in tumor volume after preoperative chemotherapy both independently shortened metastasis-free survival.
Poor histological response lost its prognostic significance.

<< Previous
Liver resection for metastatic colorectal cancer in patients with...

Next >>
Phase III noninferiority trial comparing irinotecan with...

Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, Cisplatin, and Ifosfamide
Clinical Cancer Research, 11/23/09 Relevance Score: 88%

The role of interferons in the treatment of osteosarcoma
Pediatric Blood & Cancer, 11/12/09 Relevance Score: 88%

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
British Journal of Cancer, 11/06/09 Relevance Score: 88%

Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience
Acta Oncologica, 10/26/09 Relevance Score: 88%

Tumoral Calcinosis Mimicking Recurrent Osteosarcoma
Radiology Case Reports, 10/23/09 Relevance Score: 88%